Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
315-72-0
Molecular formula
C23H29N3O
Molecular weight
363.5 g/mol
Drug class
Tricyclic-structure anxiolyticsigma-1 and sigma-2 receptor ligand
Mechanism of action
Unlike conventional tricyclic antidepressants, opipramol has relatively low monoamine-reuptake inhibition and acts predominantly through sigma-1 and sigma-2 receptor interactions, with additional affinity for histamine H1 and other central receptors. These effects modulate central anxiety and somatic symptom pathways.
Indications / reported uses
Treatment of generalised anxiety disorder and somatoform disorders in countries where opipramol is authorised.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Opipramol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Opipramol Permitted Daily Exposure (PDE) report (the Opipramol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Opipramol Occupational Exposure Limit (OEL) report (the Opipramol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.